Get started

Healthcare

DURECT CORP - NASDAQ: $DRRX FlaggingAfter breaking to higher ground a week ago on enormous volume, shares of DURECT CORP - NASDAQ:DRRX finds themselves consolidating the recent thrust in a Flag pattern on lower volume as we can observe from the Daily chart above. In addition, DRRX is now trading above all of its important moving averages 20/50/200 DMA's, which from a technical perspective, is healthy as well as constructive. Both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as we believe that its only a matter of time before the stock comes up-and-out of its Flag with its sights set on greener pastures. Thus, investors/traders may want to put DRRX front-and-center on their radars as we're anticipating a potential move into the $1.40 - $1.60 zone (and potentially higher) should the stock pop out of its pattern within the days/weeks ahead. ****NOTE DURECT Corporation - NASDAQ:DRRX to Announce Second Quarter 2019 Financial Results on August 1, 2019 After Market Close ****
NASDAQ:DRRX
by InsiderFinancial
Harmonic Cypher Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here . Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float. Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame. Follow me on twitter and instagram @ #VolatilityWatch Disclaimer: I am long NDRA. This is not a recommendation to buy or sell. Please do your homework before investing.
NLong
by follow_the_money
Davita - now a BULL trend Technicals analysis WEEKLY Davita broke a downtrend channel, and is now in a consolidation above the 200SMA. (Bull) 50SMA is now crossing above the 200SMA. (Bull) OBV and RSI show divergence, as they have moved in oposite directions since early August. (Short). However... on a daily chart , we see a decent uptrend since early June. Headlines / Fundamental On July 10th: President Donald Trump on Wednesday signed an executive order reimbursing for kidney transplants and reducing the reliance on the costly treatments at dialysis clinics. Analyst fair value target price is $79. Meaning 38% undervalued .
NYSE:DVALong
by dorfmanmaster
Will they name JCPenney JCPenny?J. C. Penney Company, Inc. is an American department store chain with 865 locations. It is a micro-cap @$187million. This upcoming earnings, this companies fate will be decided as the street awaits details of long-term plan. If the stock remains below $1 for a period of 30 consecutive business days, they will face delisting from the NYSE market. JCP August 0.50 straddle is priced for a move of 30% into the expected release of quarterly results before the bell on August 15th. Analyst note: B. Riley FBR lowers their JCP target to $0.60 from $1.30 as they believe that amid traffic/discounting pressure that has been impacting retail in general, there is downside risk to estimates.
J
by dorfmanmaster
QUOTIENT LTD - NASDAQ: $QTNT Works On Its BaseFor the better part of 2019, the shares of QUOTIENT LTD - NASDAQ: QTNT have found themselves range-bound trading within the $8 - $11 zone, while seemingly continuing to build and work on its long drawn base as is evidenced in the Daily chart above. While further work is in order, QTNT remains in decent technical shape as the stock presently finds itself trading above all of its important moving averages 20/50/200 DMA's, which constitutes a healthy technical posture. Additionally, when extending out to both the Weekly and Monthly time-frames, one can also observe that QTNT remains in fine shape as well. Therefore, we have a favorable technical picture across multiple time-frames, which bodes well. Thus, while further work is required, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead for further clues/evidence that things may be about to pick-up. In particular, should QTNT be capable of going topside of the $9.75 level, we may just witness a rapid re-test of the $11 level and perhaps a move into the $12 - $14 zone down the road.
Q
by InsiderFinancial
Bearish Butterfly SGEN has beat biotech averages significantly the past few months and has come to meet my $80 pt which also happens to make a bearish harmonic butterfly pattern. This could have a little more upside as it tests $80-81 but risk/reward would suggest a potential double top that can take this down quite a bit in a short amount of time. If I was short I would be looking to start a position. According to the bearish setup SGEN should find 50 -618 retracement before next ER bringing SGEN down to around the $69 mark. As I have outlined in this setup, SGEN is still making higher lows on long-term chart and after retracing back to $69, should see continue uptrend to ~$84 (assuming another positive ER or catalyst). Tip - Even if you rely mostly on company fundamentals, you should be aware of support/ resistance levels. Please Follow, like, comment, and share so I can continue finding awesome trades. Thank you in advance >+) Find me on Twitter or Instagram @VolatilityWatch Disclosure: I do not own a position in SGEN. I may buy/sell within the next 72 hours. This is not a note to buy or sell, please do your homework before investing.
SShort
by follow_the_money
Corindus Vascular Robotics Inc. - NYSE: $CVRS ConsolidatingTECHNICAL After breaking-out in early Spring (March) and subsequently digesting the move, CVRS broke-out once again last month (May) on enormous volume and now finds itself consolidating in a very constructive manner on lower volume as evidenced in the Daily chart above. With the stock trading just beneath its 20 DMA, yet comfortably above both its 50 and 200 DMA's, the technical picture remains positive, while the recent move into northern territory is absorbed. With that said, it now appears that it is only a matter of time before CVRS embarks on yet another potential leg higher. Thus, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as the recent consolidation comes to a conclusion with a possible break for greener pastures and a move topside of 3.10 likely triggering its next meaningful advance.
C
by InsiderFinancial
HCA: HCA Healthcare Swing 6/7% (or long term investment)Happy Fourth of July, the most American way to celebrate is profiting off healthcare. HCA Healthcare is the largest publicly traded healthcare system in the United States. Has the scale to swallow non-profits and small scale hospitals across the United States. Limits loss caused by Medicare and Medicaid patients by operating hospitals only in economically sound urban areas. Focused on regions with higher median age such as Florida. Combatting nursing shortage with a majority stake in Galen Nursing College. Lots of debt but high cashflow limits the risk. TA: Weekly MACD Cross Weekly 50ma Fell in April due to UNH earnings concerns (nothing changed fundamentally) Trading within a channel since December Took an initial position April 23rd added more at 135.15. Looking to sell some at 144.00 and hold the rest for long term investment
NYSE:HCALong
by odeaolay
SELECT MEDICAL HOLDINGS CORP - NYSE: $SEM Rounding BottomLast week, SELECT MEDICAL HOLDINGS CORP - NYSE:SEM recaptured its 200 DMA and now finds itself attempting to build on the recent grind into higher ground. In addition, when we examine the action of the Daily chart above, we can also observe that SEM appears to be coming out of a potential rounding bottom. Furthermore, the stock now finds itself trading above all of its important moving averages 20/50/200 DMA's, which is a positive from a technical viewpoint. Thus, both investors/traders may want to continue to monitor the action of SEM in the days/weeks ahead as we believe that it may have eyes initially for the open gap near $17.75, yet more likely, we envision a potential move into the $18 - $20 zone and possibly higher. Nevertheless, SEM displays favorable characteristics across multiple time-frames on the Daily; Weekly; Monthly durations and we suspect that we may just be in the early innings of a move into northern territory. ****NOTE**** SEM will report Earnings on August 1, 2019 before Market Open.
NYSE:SEM
by InsiderFinancial
Choosing an entry on UNHAfter strong earnings and a guidance upgrade, I've just been waiting for an entry point on UNH . Today we are oversold on the hourly RSI and stochastic , and I'm seeing a little bullish divergence coming in on the hourly MACD histogram. We've got support at 254.44 from the 20-day moving average, though there's not a lot of volume located here on the volume profile . I've taken a small long position here, and I'll buy more if we get down closer to 250, where there's more volume and also support from the 50-day and 200-day moving averages.
NYSE:UNHLong
by ChristopherCarrollSmith
Look for Merck to respect trend line before enteringMerck ended the day near the bottom of its parallel channel, right above a high-volume support node at 8.19 and a trend line that's parallel with channel bottom. After hours, the price has moved below both the support and the trend line, but in my experience, after hours moves don't necessarily mean much. The real test will be tomorrow after market open. If the trend line breaks, then the price will test the bottom of the channel. That will be an opportunity for an entry with a tight stop loss. Merck had a product launch after hours today (a smart pet feeder) that could help move the price upward, but honestly this stock has so many catalysts that I'm not sure investors pay much attention to them anymore. This one is pretty minor in the scheme of things. More important factors are Merck's strong analyst ratings and long history of earnings beats. One possible downside catalyst is Merck's slightly negative Earnings Surprise Prediction from Zacks.
NYSE:MRKLong
by ChristopherCarrollSmith
Mednax outrageously oversold ahead of earningsIt's not every day you see a stock get this oversold on its weekly chart. Mednax, Inc. has lost about 50% of its value over the past year due to some earnings and revenue misses and year-over-year declines. After this drop, Mednax has a very attractive P/E of 8.66. Its forward P/E of 6.84 indicates that its earnings are expected to grow. S&P Capital IQ rates the company as highly undervalued. Mednax has recently had some analyst upgrades, which could serve as an upward catalyst. Also, with an ESP of 2.13% from Zacks, Mednax may beat analyst estimates when it next reports earnings on August 1. MedData's revenue has grown over the last several earnings reports, and earnings misses have been mostly due to administrative and interest payment costs. An ongoing share buyback program has reduced the number of shares of common stock, which means the company's profit will be divided by fewer shares on the next report. On the other hand, Mednax managed to miss both its own forecasts and the analysts' estimates on its last report, despite its buyback program. I don't see a lot of signs that Mednax has made progress toward cutting costs and improving margins since then. References to "restructuring" in past earnings reports are vague, but they probably refer to the so-far unsuccessful effort to sell the MedData division of the company. S&P Capital IQ rates the company as highly financially healthy, but I think that's an exaggeration. As best I can tell, the company has some pretty high-interest debt and is burning through its cash reserves. Employee reviews on Glassdoor suggest that top executives may not be providing competent leadership. These concerns aside, Mednax's undervaluation and analyst ratings make it a potentially attractive buy ahead of earnings. Even a small earnings beat could give the stock a big bump. I see some bullish divergence on the chart that suggests a slowing of its downward momentum. I'll be watching closely for signs of positive investor sentiment, with an alert set to buy at the first sign of a breakout above the parallel channel.
NYSE:MDLong
by ChristopherCarrollSmith
Under the radar buy for growth portfolioHQY Not a major headline grabber, but growth is excellent. Now the chart has opened up technically for a run to 90+ without too much static. I am accumulating here, just a few options, but holding bigger buys for a pullback/reset to 72's for a bigger load up. The Aug 16 C90 is currently sitting at .50, and premium would significantly drop on any pullback. Load the boat then, or go ahead and get feet wet now. Either way, just don't miss this ship. Once it sails it isn't coming back to port for a while. Buy and hold people should absolutely begin adding this to a long term hold growth portfolio. Happy hunting and GLTA!!
NASDAQ:HQYLong
by UnknownUnicorn1314136
EPISODE 4/11: US HEALTH CARE XLV SECTOR-TA(TREND ANALYSIS) 2019'EPISODE 4/11: US HEALTH CARE(XLV) SECTOR Technical Analysis - 16th of July 2019. There is really not much to say. Profits in the health care sector are very reliable on the cycle. Since Trump took office, the cycle extended, and hence it formed a channel as noted in the analysis. One major risk that has always affected the health care sector is regulation and political pressures . In the upcoming 2020 election, if the Democrats(pro-regulation) take office, there might be major implications to the health care sector. In any case, 50 Quarterly/200 Monthly MA(Orange line) would be the Long-term Supports , in case the current bullish channel breaks. Structural supports are marked with Purple squares. This is just a brief "free" and very detailed analysis. Perhaps in the future I might form a premium group, to whose members I will provide all the details of my research. >> I do not share my ideas for the likes or the views. This channel is only dedicated to well informed research and other noteworthy and interesting market stories .>> However, if you'd like to support me and learn more in the greatest of details , every thumbs up or follow is greatly appreciated ! -Step_Ahead_ofthemarket- Check my previous episodes on the US Sectors in the links to related ideas down below . EPISODE 3 : TECH EPISODE 2 : ENERGY * Full Disclosure: This is just an opinion, you decide what to do with your own money. For any further references- contact me.
AMEX:XLV
by step_ahead_ofthemarket
WELL Health Technologies: Strong buy below the MA200.WELL (WELL Health Technologies Corp) is one of the hottest stocks of July as it has grown so far by 77% on a monthly basis making a jump of +175% since the beginning of June. Currently this is no time to enter this frenzy as past price action has shown that after a +170% rise and overbought levels on the 1D chart, consolidation follows and then a test of the 4H MA200. Our suggestion for this asset is a strong buy once it approaches the MA200. ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
WLong
by InvestingScope
United Health breakout above trendline resistanceUNH is looking like a great buy. Not only did it break out today above a downward trendline, but it's also near the bottom of an upward-sloping parallel channel. Fundamentals look good too, with generally positive analyst ratings and a series of recent earnings beats. Healthcare is hot right now, with its low China exposure and other sectors looking overbought. UNH next reports earnings in mid-July. Until then I expect a good medium-term bull run in UNH.
NYSE:UNHLong
by ChristopherCarrollSmith
1